Founded in 1998, Hybio is a leading peptide pharmaceutical company and the first going public in China (2011, stock code 300199). We offer a full range of peptide products (API & FDF) and services (CRO & CDMO).
Hybio Group currently owns 8 subsidiaries and branches, with its Wuhan subsidiary as an API production base, Pingshan branch as a FDF production base, Changee subsidiary as a medical device base, Dali Biotech subsidiary as hemp processing base etc...
Hybio Headquarters in Shenzhen has passed local & national NMPA GMP inspection for over 90 times, overseas FDA, EU, ANVISA, KFDA (etc.) GMP inspections for 8 times and customer audits for over 50 times. It owns over 300 invention patents and 102 PCTs, with more than 100 patents authorized.
Hybio Wuhan subsidiary is a specialized peptide API manufacturing base, which was put into production in 2019. The full capacity for peptide API can be up to 1000kg/year and the current capacity is around 300kg/year.
Main APIs are Liraglutide, Semaglutide, Tirzepatide, Glatiramer, Ganirelix, Cetrorelix, Degarelix, Atosiban, Oxytocin, Carbetocin, Terlipressin, Desmopressin, Linaclotide, Plecanatide, Leuprorelin, Triptorelin, Teriparatide, Eptifibatide, Octreotide, Lanreotide, Somatostatin, etc.